newsfilter
← Latest News
Business Wire·

Aimmune Therapeutics Announces Additional $200 Million Equity Investment by Nestlé Health Science

BRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced that Nestlé Health Science will make an additional equity investment in Aimmune of $200 million, bringing Nestlé’s total investment in Aimmune to date to $473 million.